Journal
HAEMATOLOGICA
Volume 100, Issue 7, Pages 945-954Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2014.122069
Keywords
-
Categories
Funding
- Lymphoma Research Foundation (LRF) [285871]
- American Cancer Society [RSG-06-011-01-CDD]
- National Institutes of Health [R01-GM086225]
- National Institutes of Health, CLL Research Consortium Grant [PO1-CA081534]
- UC San Diego Foundation Blood Cancer Research Fund
- Bennett Family Foundation
- Moores Cancer Center-UCSD
Ask authors/readers for more resources
RNA splicing plays a fundamental role in human biology. Its relevance in cancer is rapidly emerging as demonstrated by spliceosome mutations that determine the prognosis of patients with hematologic malignancies. We report studies using FD-895 and pladienolide-B in primary leukemia cells derived from patients with chronic lymphocytic leukemia and leukemia-lymphoma cell lines. We found that FD-895 and pladienolide-B induce an early pattern of mRNA intron retention - spliceosome modulation. This process was associated with apoptosis preferentially in cancer cells as compared to normal lymphocytes. The pro-apoptotic activity of these compounds was observed regardless of poor prognostic factors such as Del(17p), TP53 or SF3B1 mutations and was able to overcome the protective effect of culture conditions that resemble the tumor microenvironment. In addition, the activity of these compounds was observed not only in vitro but also in vivo using the A20 lymphoma murine model. Overall, these findings give evidence for the first time that spliceosome modulation is a valid target in chronic lymphocytic leukemia and provide an additional rationale for the development of spliceosome modulators for cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available